ClinicalTrials.gg
RecruitingNCT05740722NorsemanUpdated Jan 11, 2024

Nicotinamide Riboside Supplementation In Progressive Multiple Sclerosis

A Phase 2 interventional study of Nicotinamid riboside and Placebo in Multiple Sclerosis and Progressive Multiple Sclerosis, sponsored by Haukeland University Hospital. Recruiting at 1 site in Norway. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-01-11.

Sponsored by Haukeland University Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 56 studies in Multiple Sclerosis with a site in Norway — 2 open to participants now, 9 under way, 3 of them phase 3. Multiple Sclerosis · Norway.

Planned enrollment
22nd of 43
300 · median 300
Started
2023
with 1 other
Phase 2
9 of 56
1 open now
Registered
52nd of 56
by date
Lead sponsor
4 of 56
Haukeland University Hospital

Among the 56 studies in Multiple Sclerosis with a site in Norway, this one is the 22nd largest by planned enrollment of the 43 interventional ones that give a count, is one of 2 that started in 2023, is one of 9 in phase 2, and was the 52nd registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

2 of the 56 studies in Multiple Sclerosis with a site in Norway are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies in Multiple Sclerosis with a site in Norway, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and efficacy of Nicotinamide riboside (NR) for treatment of patients with progressive multiple sclerosis.

The main question it aims to answer is:

  • Does NR delay disability progression in progressive multiple sclerosis?

Participants will be treated with NR or placebo for 30 months,

Read the detailed description

After being informed about the study and risks, all patients giving written informed consent will undergo a screening period to determine eligibility for study entry.

At baseline patients who meet the eligibility requirements will be randomised in a double- blinded manner (patient and investigator) in a 1:1 ratio to nicotinamide riboside (1000 mg daily) or placebo (once a day)

03

Conditions studied

  • Multiple Sclerosis
  • Progressive Multiple Sclerosis

Keywords

  • nicotinamid riboside
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A diagnosis of progressive MS (secondary; SPMS or primary; PPMS) according to the 2013 revisions of clinical course of multiple sclerosis and the 2017 revisions of the McDonald criteria.
  • Aged 18-65 years.
  • EDSS 3-6.5
  • Able to perform T25FW test
  • The participant must have documented evidence of disability progression observed during the 24 months before screening.
  • With or without a stable disease modifying therapy during the last three months.
  • Written for study participation.

Exclusion criteria

Exclusion Criteria:

  • A diagnosis of relapsing MS according to the revisions of the McDonald criteria
  • Neoplastic disease at baseline
  • Previous history of malignant melanoma or breast cancer
  • Stable phase of a progressive disease course
  • Pregnancy or lactating female patients
  • Dementia or other neurodegenerative disorder at baseline visit
  • Comorbidity (psychiatric or somatic) that precludes study participation
  • Use of high dose vitamin B3 supplementation within 30 days of enrolment
  • Genetically confirmed mitochondrial disease or metabolic disorder
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Placebo

    Placebo vs study drug

    Dietary Supplement: Placebo

  • Experimental
    Nicotinamid Riboside

    Placebo vs study drug

    Dietary Supplement: Nicotinamid riboside

Interventions

  • Dietary supplementNicotinamid riboside

    500 mg x 2 po

  • Dietary supplementPlacebo

    Placebo tablets

06

What researchers measure

Primary outcomes

  1. Proportion of patients with sustained disability progression over the treatment period

    Defined as an increase in either expanded disability status scale (EDSS), timed 25 foot -walk test (T25W) or 9-hole-peg test. EDSS is measured in scores from 0 - 10. The higher the score the less ambulatory ability. Progression is defined as an increase of \>/=1.0 point if baseline EDSS is \</= 5.5 or an increase of \>/=0.5 point if baseline EDSS is \>/= 5.5. Progression in T25WT and 9HPT is defined as an increase of 20% from baseline measures in minutes/seconds.

    Time frame: Baseline to month 30

Secondary outcomes

  1. To determine the efficacy of NR compared with placebo, as reflected by EDSS

    Proportion of patients with sustained disability progression over the treatment period

    Time frame: Baseline to month 30

  2. To determine the efficacy of NR compared with placebo, as reflected by 25-footwalk

    Proportion of patients with sustained disability progression over the treatment period

    Time frame: Baseline to month 30

  3. To determine the efficacy of NR compared with placebo, as reflected by 9-Hole Peg test

    Proportion of patients with sustained disability progression over the treatment period

    Time frame: Baseline to month 30

  4. To determine the efficacy of NR compared with placebo, as reflected by total volume of T2 lesions on MRI scans of the brain

    MRI

    Time frame: Baseline to month 24

  5. To determine the efficacy of NR compared with placebo, as reflected by formation of lesions

    MRI

    Time frame: Baseline to month 24

  6. Changes in brain atrophy in NR-treated patients with primary progressive multiple sclerosis as compared with placebo

    MRI

    Time frame: Baseline to month 24

  7. Time to onset of sustained disability progression over the treatment period

    Increase in either EDSS, T25FW or 9HPT that is sustained for at least 6 months

    Time frame: Baseline to month 30

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Aug 2027, 50 months after the start.

Of 49 non-industry phase 2 interventional studies under Multiple Sclerosis, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 68. This study's planned 50 months is above that.

Counting every sponsor, half of 92 studies reached it within 36 months; a quarter within 20 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2023
First posted
Feb 23, 2023
StartActual
May 3, 2023
Primary completionEst.
Aug 1, 2027
CompletionEst.
Dec 30, 2027
Last update
Jan 11, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05740722
Responsible party
Sponsor
First posted
Feb 23, 2023
Start date
May 3, 2023
Primary completion
Aug 1, 2027 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Jan 11, 2024

Study contacts

Kjell-Morten Myhr
Contact
kjell-morten.myhr@helse-bergen.no
+47 55976031
Øivind Torkildsen
Contact
oivind.fredvik.grytten.torkildsen@helse-bergen.no
+4755977039
Kjell-Morten Myhr
study director · Haukeland University Hopsital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion